Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Rowland

Showing results (111-120 of 155) with videos related to

Pageof 16
Sort By:
Trials|December 29, 2017
Azithromycin versus placebo for the treatment of HIV-associated chronic lung disease in children and adolescents (BREATHE trial): study protocol for a randomised controlled trialCarmen Gonzalez-Martinez, Katharina Kranzer, Grace McHugh, et al.
European Journal of Immunology|August 9, 2021
Clonotypic architecture of a Gag-specific CD8+ T-cell response in chronic human HIV-2 infectionEirini Moysi, Samuel Darko, Ester Gea-Mallorquí, et al.
European Journal of Immunology|April 16, 2005
CD8+ T cell responses to human immunodeficiency viruses type 2 (HIV-2) and type 1 (HIV-1) gag proteins are distinguishable by magnitude and breadth but not cellular phenotypeGeraldine M A Gillespie, Susana Pinheiro, Mohammad Sayeid-Al-Jamee, et al.
The Journal of Infectious Diseases|May 13, 2009
HV-1-specific cytotoxic T lymphocytes and breast milk HIV-1 transmissionGrace C John-Stewart, Dorothy Mbori-Ngacha, Barbara Lohman Payne, et al.
Journal of Virology|April 28, 2006
Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccineLucy Dorrell, Hongbing Yang, Beatrice Ondondo, et al.
Science Translational Medicine|June 24, 2011
Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infantsMartin O C Ota, Aderonke A Odutola, Patrick K Owiafe, et al.
Journal of Virology|November 11, 2011
Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomesThushan I de Silva, Marlén Aasa-Chapman, Matthew Cotten, et al.
Plos One|December 7, 2007
High pro-inflammatory cytokine secretion and loss of high avidity cross-reactive cytotoxic T-cells during the course of secondary dengue virus infectionTao Dong, Edward Moran, Nguyen Vinh Chau, et al.
The EMBO Journal|September 20, 2017
Snapin promotes HIV-1 transmission from dendritic cells by dampening TLR8 signalingElham Khatamzas, Madeleine Maria Hipp, Daniel Gaughan, et al.
The Journal of Clinical Investigation|September 8, 2007
Robust Gag-specific T cell responses characterize viremia control in HIV-2 infectionAleksandra Leligdowicz, Louis-Marie Yindom, Clayton Onyango, et al.
Pageof 16

Showing results (111-120 of 155) with videos related to

Sort By:
Pageof 16
Trials|December 29, 2017
Azithromycin versus placebo for the treatment of HIV-associated chronic lung disease in children and adolescents (BREATHE trial): study protocol for a randomised controlled trialCarmen Gonzalez-Martinez, Katharina Kranzer, Grace McHugh, et al.
European Journal of Immunology|August 9, 2021
Clonotypic architecture of a Gag-specific CD8+ T-cell response in chronic human HIV-2 infectionEirini Moysi, Samuel Darko, Ester Gea-Mallorquí, et al.
European Journal of Immunology|April 16, 2005
CD8+ T cell responses to human immunodeficiency viruses type 2 (HIV-2) and type 1 (HIV-1) gag proteins are distinguishable by magnitude and breadth but not cellular phenotypeGeraldine M A Gillespie, Susana Pinheiro, Mohammad Sayeid-Al-Jamee, et al.
The Journal of Infectious Diseases|May 13, 2009
HV-1-specific cytotoxic T lymphocytes and breast milk HIV-1 transmissionGrace C John-Stewart, Dorothy Mbori-Ngacha, Barbara Lohman Payne, et al.
Journal of Virology|April 28, 2006
Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccineLucy Dorrell, Hongbing Yang, Beatrice Ondondo, et al.
Science Translational Medicine|June 24, 2011
Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infantsMartin O C Ota, Aderonke A Odutola, Patrick K Owiafe, et al.
Journal of Virology|November 11, 2011
Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomesThushan I de Silva, Marlén Aasa-Chapman, Matthew Cotten, et al.
Plos One|December 7, 2007
High pro-inflammatory cytokine secretion and loss of high avidity cross-reactive cytotoxic T-cells during the course of secondary dengue virus infectionTao Dong, Edward Moran, Nguyen Vinh Chau, et al.
The EMBO Journal|September 20, 2017
Snapin promotes HIV-1 transmission from dendritic cells by dampening TLR8 signalingElham Khatamzas, Madeleine Maria Hipp, Daniel Gaughan, et al.
The Journal of Clinical Investigation|September 8, 2007
Robust Gag-specific T cell responses characterize viremia control in HIV-2 infectionAleksandra Leligdowicz, Louis-Marie Yindom, Clayton Onyango, et al.
Pageof 16